The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Vaccines and Biologics: What Rheumatologists Need to Know

Vaccines and Biologics: What Rheumatologists Need to Know

December 1, 2014 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
The who, what & when of vaccinology

Patients with rheumatic diseases are at a higher risk for infection as a function of the disease process. The immune system effects of biologic and steroid medications used in treatment can exacerbate this.

You Might Also Like
  • Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • EULAR 2014: Non-Tumor Necrosis Factor Biologics Update
Explore This Issue
December 2014
Also By This Author
  • Colcrys Approval Triggers Questions

Because of this, the use of vaccines to prevent illness is an important intervention in these individuals. However, there is some concern among physicians that we don’t understand how vaccines, medications and the disease-related impacts on the immune system interact in most cases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Several Questions

“Several questions remain, including the role of biological agents on hampering the immune response to vaccines, whether this can influence the efficacy of vaccines and more detailed information about the safety profile of vaccines in this particular subgroup of patients,” says Professor David Isenberg, from the Centre for Rheumatology at the University College of London in the United Kingdom. “There are published recommendations on the use of vaccination in patients with rheumatic disease on conventional immunosuppressives. There are no specific recommendations for vaccination in patients treated with biologics.”

To address some of these issues, Prof. Isenberg and Isabel Ferreira, MD, Hospital Prof. Doutor Fernando Fonseca in Amadora, Portugal, published a review of the literature on the subject in the Annals of Rheumatic Diseases.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Little Available Guidance

“There really wasn’t much guidance available, but I wanted to see exactly how much information existed,” says Dr. Isenberg. “While it isn’t entirely a data-free area, there is still a very restricted amount of information out there, and that is an issue. The more we got into this research, the more holes we found in our knowledge.”

Their research did result in some specific suggestions. One is that it’s important to complete a thorough assessment of vaccination status before beginning the biologic regimen.

Assessment Before Starting “

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Kotton
Dr. Kotton

Prior to administering immunomodulatory therapy, it would probably be best if patients were given any needed vaccinations at least a month prior to the initial dose, especially for live viral vaccines,” says Camille Kotton, MD, clinical director of transplant infectious diseases at Massachusetts General Hospital in Boston.

She further suggests that rheumatologists may want to consider referring their patients for an evaluation by an infectious disease (ID) specialist prior to beginning the medication.

“As an immunocompromised host ID specialist, I believe such an evaluation can be very helpful when patients are about to undergo immunomodulatory therapy,” she says. “When I see such patients, they are assessed for latent infections, such as tuberculosis, and other endemic pathogens and prophylaxis issues are considered. I evaluate their vaccination and serologic status, and then administer the necessary vaccines.”

Timing Considerations

The Annals article suggested that timing of vaccinations can be important, may change depending on the type of medication being used and should be contemplated only during stable disease.

Pages: 1 2 3 4 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, Immune System, interaction, Research, Rheumatic Disease, rheumatologist, rheumatology, rituximab, Ullman, vaccinesIssue: December 2014

You Might Also Like:
  • Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • EULAR 2014: Non-Tumor Necrosis Factor Biologics Update
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)